Royalty Pharma
RPRX
$0.07 (0.25%)
1D
1W
3M
1Y
5Y
ALL
Royalty Pharma plc is engaged in investing in late stage biopharmaceutical products. The Company invests in academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The Company’s portfolio of pharmaceutical investment includes investments in commercial products and development-stage product candidates. Its portfolio investments include AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko, Trikafta and OXLUMO.
Open
Prior close
Today's high
Today's low
52 Week high
52 Week low
GlobeNewsWire • 2 days ago • RPRX
Royalty Pharma Appoints Eric Schneider as Chief Technology OfficerSeeking Alpha • 17 days ago • RPRX
Royalty Pharma: We Continue To Like The Strategy And Sell-Off Is OverdoneGlobeNewsWire • 18 days ago • RPRX
Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding AgreementGlobeNewsWire • 18 days ago • RPRX
Royalty Pharma to Present at Upcoming Investor ConferencesCharts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.